Glenmark Receives US FDA Inspection Report For Goa Facility; Shares Rise 0.28%

Mumbai, September 23: Glenmark Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its formulations manufacturing facility in Goa, with the inspection classified as Voluntary Action Indicated (VAI).

Glenmark Receives US FDA Report For Goa Facility

According to the company’s exchange disclosure, the US FDA conducted an inspection of Glenmark’s manufacturing facility in Goa between June 22, 2026 and June 30, 2026.

The company has now received the Establishment Inspection Report following the inspection. The filing identifies the outcome as a Voluntary Action Indicated classification.

The EIR relates to Glenmark’s formulations manufacturing operations at the Goa facility. The company disclosed the development to the stock exchanges under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations.

Stock Market Snapshot

Glenmark Pharmaceuticals shares were trading at ₹2,468.30 as of 9:43 AM IST on September 23, 2026, up ₹6.90, or 0.28%, according to the market data shown.

The stock moved between roughly ₹2,462 and ₹2,473 during the early trading session before easing slightly from the day’s higher levels. It was quoted at ₹2,468.30 at the latest available time.

The Glenmark share price was therefore trading marginally higher as the company disclosed the US FDA inspection report for its Goa facility.

What The US FDA Inspection Covered

The inspection was conducted at Glenmark’s Goa formulations manufacturing facility over an eight-day period from June 22 to June 30, 2026.

The company has disclosed the receipt of the EIR and its VAI classification but the exchange filing does not provide further details on specific observations from the inspection.

The regulatory update therefore confirms the receipt and classification of the inspection report rather than providing additional details on individual observations or corrective actions.

Glenmark’s Global Pharmaceutical Operations

Glenmark Pharmaceuticals describes itself as a research-led global pharmaceutical company focused on innovation and access to medicines.

According to the company’s profile included in the disclosure, Glenmark operates 11 manufacturing facilities across four continents and has six R&D centres. Its commercial footprint extends across more than 80 countries.

The company’s portfolio includes branded, innovative, generic and consumer healthcare products, with key therapeutic focus areas including respiratory, dermatology and oncology.

Glenmark also said it was among the top 100 pharmaceutical companies globally by pharmaceutical sales in 2024.

Conclusion

Glenmark Pharmaceuticals has received the US FDA’s Establishment Inspection Report for its Goa formulations manufacturing facility following an inspection conducted from June 22 to June 30, 2026.

The report carries a Voluntary Action Indicated classification, while the company has not disclosed specific inspection observations in the exchange filing. Glenmark shares were trading at ₹2,468.30, up 0.28%, as of 9:43 AM IST on September 23, 2026.

Source:

• https://www.nseindia.com/get-quote/equity/GLENMARK/Glenmark-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/GLENMARK_23092026083959_SEPressRelease23092026.pdf